COMP <GO>
QGEN vs RGEN // RSI-14 & 200D SMA MOMENTUM
Qiagen N.V. (NYSE) VS. Repligen Corporation (NASDAQ) • 15-METRIC TALLY: QGEN 10
— RGEN 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: QGEN
LAST: $50.35 (+0.26%) • MKT CAP: $10.35B
rsi-technicals
71.0
LAST: $172.95 (-2.25%) • MKT CAP: $10.03B
rsi-technicals
48.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. RGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | RGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 88.20% | -26.00 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 2.30% | +5.70 | QGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 95.0x | -77.40 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 0.88% | +3.49 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 1.80% | +20.50 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 1.60% | +18.70 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | -3.30% | +9.00 | QGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 0.00% | +0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 9.31 | -5.77 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 71.0 | 48.0 | +23.00 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.04 | -0.09 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.35B | $10.03B | $317.9M | QGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | RGEN REV | QGEN GROSS % | RGEN GROSS % | QGEN FCF | RGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $154.5M | 62.2% | — | $453.3M | $93.9M |
| FY 2024 | $1.98B | $98.3M | 48.9% | — | $506.4M | $149.7M |
| FY 2023 | $1.97B | $133.6M | — | — | $371.0M | $113.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
RGEN // BETA 1.04